OncoCyte Corporation (OCX) Social Stream
ONCOCYTE CORP (OCX) Price Targets From Analysts
Use the tables below to see what analysts covering ONCOCYTE CORP think about its future price and what recommendations they have for investors and traders.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-09 | 3 | $11 | $5 | $7.75 | $0.39 | 1887.18% |
| 2021-11-10 | 3 | $11 | $7 | $8.333 | $0.39 | 2036.67% |
| 2021-12-16 | 3 | $11 | $5 | $7.666 | $0.39 | 1865.64% |
| 2022-01-06 | 5 | $11 | $3.1 | $6.525 | $0.39 | 1573.08% |
| 2022-02-01 | 5 | $11 | $3.1 | $5.84 | $0.39 | 1397.44% |
| 2022-03-17 | 5 | $11 | $1.8 | $5.225 | $0.39 | 1239.74% |
| 2022-04-01 | 5 | $11 | $1.8 | $4.95 | $0.39 | 1169.23% |
| 2022-05-16 | 5 | $11 | $1.4 | $4.85 | $0.39 | 1143.59% |
| 2022-06-06 | 5 | $11 | $1.25 | $4.662 | $0.39 | 1095.38% |
| 2022-08-11 | 6 | $4 | $1.25 | $2.35 | $0.39 | 502.56% |
| 2022-08-17 | 6 | $4 | $1.25 | $2.37 | $0.39 | 507.69% |
| 2022-09-01 | 6 | $4 | $1.15 | $2.35 | $0.39 | 502.56% |
| 2022-11-01 | 5 | $4 | $0.9 | $2.3 | $0.39 | 489.74% |
| 2022-11-11 | 5 | $4 | $0.9 | $2.16 | $0.39 | 453.85% |
| 2022-11-14 | 5 | $4 | $0.9 | $2.06 | $0.39 | 428.21% |
| 2022-11-18 | 5 | $4 | $0.5 | $1.96 | $0.39 | 402.56% |
| 2022-12-07 | 5 | $4 | $0.5 | $1.46 | $0.39 | 274.36% |
The Trend in the Analyst Price Target
Over the past 13 months, OCX's average price target has gone down $6.29.
Over the past 38 weeks, OCX's average upside potential has been 260.82%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-04-01 | 5 | 11 | 1.80 | 4.95 | 1.480 | 234.46% |
| 2022-08-17 | 6 | 4 | 1.25 | 2.37 | 0.874 | 171.17% |
| 2022-11-01 | 5 | 4 | 0.90 | 2.30 | 0.707 | 225.32% |
| 2022-11-18 | 5 | 4 | 0.50 | 1.96 | 0.440 | 345.45% |
| 2022-12-01 | 5 | 4 | 0.50 | 1.46 | 0.475 | 207.37% |
OCX Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 2.4 | 1 | 1 | 3 | 0 | 0 | 5 |
The Trend in the Broker Recommendations
Over the past 26 weeks, OCX's average broker recommendation rating worsened by 0.4.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- In terms of how ONCOCYTE CORP fares relative to all US stocks, note that its average analyst price target is greater than 75.71% of that group.
- In terms of how ONCOCYTE CORP fares relative to all US stocks, note that its upside potential (average analyst target price relative to current price) is greater than 2119.06% of that group.
- In terms of how ONCOCYTE CORP fares relative to stocks in the small market cap category, note that its variance in analysts' estimates is lower than -1846.12% of that group.
- In terms of how ONCOCYTE CORP fares relative to Healthcare stocks, note that its number of analysts covering the stock is higher than 634.32% of that group.
Stocks similar to ONCOCYTE CORP in the Pharmaceutical Products industry regarding analyst recommendations and price targets are TRIB, ABIO, and LHDX.
View All Top Stocks by Price Target
Is OCX a Buy, Hold or Sell? See the POWR Ratings now!